Trial · NCT02713529
Participant flow21
How many started, completed or left each group, period by period.
1 to 20 of 21
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Part 1, Cohort 2: AMG 820 1100 mg + Pem 200 mg | 8 | |
| Overall Study | STARTED | Part 1, Cohort 1: AMG 820 1400 mg + Pem 200 mg | 7 | |
| Overall Study | STARTED | Part 2, Group 1: CRC MMR-proficient | 42 | |
| Overall Study | STARTED | Part 2, Group 2: Pancreatic Cancer | 31 | |
| Overall Study | STARTED | Part 2, Group 3: NSCLC PD-L1 Low, Naïve | 4 | |
| Overall Study | STARTED | Part 2, Group 4a: Refractory / Relapsing NSCLC PD-L1 Low | 19 | |
| Overall Study | STARTED | Part 2, Group 4b: Refractory/Relapsing NSCLC PD-L1 High | 6 | |
| Overall Study | COMPLETED | Part 1, Cohort 2: AMG 820 1100 mg + Pem 200 mg | 1 | |
| Overall Study | COMPLETED | Part 1, Cohort 1: AMG 820 1400 mg + Pem 200 mg | 3 | |
| Overall Study | COMPLETED | Part 2, Group 1: CRC MMR-proficient | 11 | |
| Overall Study | COMPLETED | Part 2, Group 2: Pancreatic Cancer | 2 | |
| Overall Study | COMPLETED | Part 2, Group 3: NSCLC PD-L1 Low, Naïve | 1 | |
| Overall Study | COMPLETED | Part 2, Group 4a: Refractory / Relapsing NSCLC PD-L1 Low | 5 | |
| Overall Study | COMPLETED | Part 2, Group 4b: Refractory/Relapsing NSCLC PD-L1 High | 2 | |
| Overall Study | NOT COMPLETED | Part 1, Cohort 2: AMG 820 1100 mg + Pem 200 mg | 7 | |
| Overall Study | NOT COMPLETED | Part 1, Cohort 1: AMG 820 1400 mg + Pem 200 mg | 4 | |
| Overall Study | NOT COMPLETED | Part 2, Group 1: CRC MMR-proficient | 31 | |
| Overall Study | NOT COMPLETED | Part 2, Group 2: Pancreatic Cancer | 29 | |
| Overall Study | NOT COMPLETED | Part 2, Group 3: NSCLC PD-L1 Low, Naïve | 3 | |
| Overall Study | NOT COMPLETED | Part 2, Group 4a: Refractory / Relapsing NSCLC PD-L1 Low | 14 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02713529/flow